News headlines about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5695005400064 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of analysts recently weighed in on SBPH shares. Cantor Fitzgerald set a $29.00 target price on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 16th. Chardan Capital reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, November 6th. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, B. Riley assumed coverage on Spring Bank Pharmaceuticals in a research report on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $27.25.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) traded down $0.47 during mid-day trading on Wednesday, reaching $12.97. The company’s stock had a trading volume of 60,500 shares, compared to its average volume of 50,900. Spring Bank Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $18.93. The company has a market capitalization of $174.06, a P/E ratio of -4.72 and a beta of 2.04.

COPYRIGHT VIOLATION NOTICE: “Spring Bank Pharmaceuticals (SBPH) Receiving Somewhat Positive Press Coverage, Study Shows” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/01/03/spring-bank-pharmaceuticals-sbph-receiving-somewhat-positive-press-coverage-study-shows.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Insider Buying and Selling by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.